- Advanced search
|Approved drug?||Yes (source: FDA (2013))|
|International Nonproprietary Names|
|Search PubMed clinical trials||trastuzumab emtansine|
|Search PubMed titles||trastuzumab emtansine|
|Search PubMed titles/abstracts||trastuzumab emtansine|
|Trastuzumab emtansine is a antobody-drug conjugate (ADC) containing a targeting antibody (anti-erbB2) conjugated to a cytotoxic drug (mertansine or DM1) . The PubChem ID for the mertasine component compound is CID 11343137. Mertansine (or DM1) is a macrolide of the ansamycin type and can be isolated from plants of the genus Maytenus. It is known as a maytansinoid. This agent binds to the rhizoxin binding site on β- tubulin and functions in a similar fashion to the Vinca alkaloids.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.